Heydendael VM - Search Results

1

The burden of psoriasis is not determined by disease severity only.

Heydendael VM, de Borgie CA, Spuls PI, Bossuyt PM, Bos JD, de Rie MA. Heydendael VM, et al. J Investig Dermatol Symp Proc. 2004 Mar;9(2):131-5. doi: 10.1111/j.1087-0024.2004.09115.x. J Investig Dermatol Symp Proc. 2004. PMID: 15083779 Free article. Clinical Trial.

2

Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis.

Heydendael VM, Spuls PI, Opmeer BC, de Borgie CA, Reitsma JB, Goldschmidt WF, Bossuyt PM, Bos JD, de Rie MA. Heydendael VM, et al. N Engl J Med. 2003 Aug 14;349(7):658-65. doi: 10.1056/NEJMoa021359. N Engl J Med. 2003. PMID: 12917302 Free article. Clinical Trial.

3

Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine.

Opmeer BC, Heydendael VM, De Borgie CA, Spuls PI, Bossuyt PM, Bos JD, De Rie MA. Opmeer BC, et al. Among authors: heydendael vm. Arch Dermatol. 2004 Jun;140(6):685-90. doi: 10.1001/archderm.140.6.685. Arch Dermatol. 2004. PMID: 15210458 Clinical Trial.

4

Cyclosporin trough levels: is monitoring necessary during short-term treatment in psoriasis? A systematic review and clinical data on trough levels.

Heydendael VM, Spuls PI, Ten Berge IJ, Opmeer BC, Bos JD, de Rie MA. Heydendael VM, et al. Br J Dermatol. 2002 Jul;147(1):122-9. doi: 10.1046/j.1365-2133.2002.04836.x. Br J Dermatol. 2002. PMID: 12100194 Review.

5

Cyclosporin A and methotrexate are equally effective in reducing T cell numbers in psoriatic skin lesions but have no consistent effect on IFN-gamma and IL-4 expression in psoriatic skin in situ.

Piskin G, Heydendael VM, de Rie MA, Bos JD, Teunissen MB. Piskin G, et al. Among authors: heydendael vm. Arch Dermatol Res. 2003 Mar;294(12):559-62. doi: 10.1007/s00403-002-0353-8. Epub 2002 Dec 14. Arch Dermatol Res. 2003. PMID: 12624782 Clinical Trial. No abstract available.

6

Systemic treatment with either cyclosporin A or methotrexate does not influence the T helper 1/T helper 2 balance in psoriatic patients.

Rentenaar RJ, Heydendael VM, van Diepen FN, de Rie MA, ten Berge IJ. Rentenaar RJ, et al. Among authors: heydendael vm. J Clin Immunol. 2004 Jul;24(4):361-9. doi: 10.1023/B:JOCI.0000029107.47085.1b. J Clin Immunol. 2004. PMID: 15163892 Clinical Trial.

7

Patients with moderate-to-severe plaque psoriasis preferred oral therapies to phototherapies: a preference assessment based on clinical scenarios with trade-off questions.

Opmeer BC, Heydendael VM, deBorgie CA, Spuls PI, Bossuyt PM, Bos JD, de Rie MA. Opmeer BC, et al. Among authors: heydendael vm. J Clin Epidemiol. 2007 Jul;60(7):696-703. doi: 10.1016/j.jclinepi.2006.10.011. Epub 2007 Jan 16. J Clin Epidemiol. 2007. PMID: 17573985

8

In situ demonstration of CD40- and CD154-positive cells in psoriatic lesions and keratinocyte production of chemokines by CD40 ligation in vitro.

Pasch MC, Timár KK, van Meurs M, Heydendael VM, Bos JD, Laman JD, Asghar SS. Pasch MC, et al. Among authors: heydendael vm. J Pathol. 2004 Jul;203(3):839-48. doi: 10.1002/path.1581. J Pathol. 2004. PMID: 15221944

9

Analysis of risk factors in psoriatic patients with methotrexate-induced increases in transaminase levels.

Heydendael VM, Spuls PI, Bossuyt PM, Bos JD, de Rie MA. Heydendael VM, et al. Arch Dermatol. 2004 Oct;140(10):1289-90. doi: 10.1001/archderm.140.10.1289. Arch Dermatol. 2004. PMID: 15492205 No abstract available.

10

Acute blue patch on the forearm.

Heydendael VM, Hoekzema R. Heydendael VM, et al. Arch Dermatol. 2007 Jul;143(7):937-42. doi: 10.1001/archderm.143.7.937-a. Arch Dermatol. 2007. PMID: 17638744 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

12 results

Search Page